Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Michael T. Lotze

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3988-5419; OpenAlex author ID A5024528047, A5111436843; NIH RePORTER profile ID 1888494. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 4)
Trials
0
Grants
1
Labs led
1
Collaborators
62
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: 1 paper · 2018: 2 papers, 1 grant · 2019: 2 papers · 2020: 4 papers · 2021: 6 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 25

  1. Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Co-author DOI 10.1158/1078-0432.ccr-25-1110↗
  2. Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: A Review of Methods and Applications. Last author DOI 10.3390/ijms252011013↗
  3. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2023.7070↗
  4. Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Co-author DOI 10.1016/j.drudis.2021.09.011↗
  5. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  6. Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/cji.0000000000000370↗
  7. Computational modeling of cell signaling and mutations in pancreatic cancer Co-author DOI 10.1101/2021.06.08.447557↗
  8. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Co-author DOI 10.1111/cts.13029↗
  9. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2019-320441↗
  10. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  11. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Last author DOI 10.1158/1078-0432.ccr-19-4042↗
  12. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08094-0↗
  13. SMAD4 Loss is Associated with Response to Neoadjuvant Chemotherapy with Hydroxychloroquine in Patients with Pancreatic Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-125334/v1↗
  14. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2214/ajr.19.21152↗
  15. The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Co-author DOI 10.1007/s00277-019-03692-0↗
  16. Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-3064↗
  17. Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. Co-author DOI 10.1186/s12885-018-4584-2↗
  18. RAGE-specific single chain Fv for PET imaging of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0192821↗
  19. Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Co-author DOI 10.1038/cr.2017.51↗
  20. The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Co-author DOI 10.1038/cgt.2015.21↗
  21. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and develop… Last author DOI 10.1097/mpa.0000000000000298↗
  22. Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4566-4↗
  23. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Co-author DOI 10.1038/cddis.2014.445↗
  24. Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Last author DOI 10.1097/mpa.0b013e3182854ab0↗
  25. Pancreatic cancer is not noble. Co-author DOI 10.1159/000334593↗

Grants 1

  1. Pancreatic Ductal Adenocarcinoma is a disease of constitutive autophagy R01CA181450↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Herbert J. Zeh · 17 shared papers, 1 shared grant, 2013–2021 · strength 1.73
  2. Amer H. Zureikat · 10 shared papers, 2015–2026 · strength 1.24
  3. Aatur Dilip Singhi · 10 shared papers, 2015–2026 · strength 1.14
  4. Brian A. Boone · 12 shared papers, 2015–2021 · strength 1.11
  5. Pranav Murthy · 8 shared papers, 2018–2026 · strength 1.10
  6. Nathan Bahary · 9 shared papers, 2015–2023 · strength 0.92
  7. Alessandro Paniccia · 4 shared papers, 2021–2026 · strength 0.66
  8. Melissa Ellen Hogg · 5 shared papers, 2020–2021 · strength 0.54
  9. Daolin Tang · 8 shared papers, 2013–2021 · strength 0.53
  10. Asmita Chopra · 3 shared papers, 2021–2026 · strength 0.49
  11. David L. Bartlett · 5 shared papers, 2014–2021 · strength 0.34
  12. Genia Dubrovsky · 1 shared paper, 2024 · strength 0.31
  13. Rui Kang · 4 shared papers, 2014–2021 · strength 0.30
  14. Renee R. Anderko · 1 shared paper, 2026 · strength 0.26
  15. Sebastiaan Ceuppens · 1 shared paper, 2026 · strength 0.26
  16. Jennifer Lee Miller-Ocuin · 3 shared papers, 2018–2020 · strength 0.25
  17. Naomi H. Fei · 2 shared papers, 2020–2021 · strength 0.24
  18. Jacob Cuyler · 1 shared paper, 2022 · strength 0.19
  19. Xiang‐Qun Xie · 1 shared paper, 2022 · strength 0.19
  20. Samer S. AlMasri · 1 shared paper, 2023 · strength 0.17
  21. Cheryl A. Telmer · 1 shared paper, 2021 · strength 0.15
  22. Nataša Miškov-Živanov · 1 shared paper, 2021 · strength 0.15
  23. Christof Kaltenmeier · 1 shared paper, 2021 · strength 0.15
  24. Randall E. Brand · 1 shared paper, 2021 · strength 0.12
  25. Jin Huang · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.